BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

Chaoyang Sun, Jun Yin, Yong Fang, Jian Chen, Kang Jin Jeong, Xiaohua Chen, Christopher P. Vellano, Zhenlin Ju, Wei Zhao, Dong Zhang, Yiling Lu, Funda Meric-Bernstam, Timothy A. Yap, Maureen Hattersley, Mark J. O'Connor, Huawei Chen, Stephen Fawell, Shiaw Yih Lin, Guang Peng, Gordon Mills

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Poly(ADP-ribose) polymerase inhibitors (PARPi) are selectively active in cells with homologous recombination (HR) deficiency (HRD) caused by mutations in BRCA1, BRCA2, and other pathway members. We sought small molecules that induce HRD in HR-competent cells to induce synthetic lethality with PARPi and extend the utility of PARPi. We demonstrated that inhibition of bromodomain containing 4 (BRD4) induced HRD and sensitized cells across multiple tumor lineages to PARPi regardless of BRCA1/2, TP53, RAS, or BRAF mutation status through depletion of the DNA double-stand break resection protein CtIP (C-terminal binding protein interacting protein). Importantly, BRD4 inhibitor (BRD4i) treatment reversed multiple mechanisms of resistance to PARPi. Furthermore, PARPi and BRD4i are synergistic in multiple in vivo models. Sun et al. show that inhibition of BRD4 induces homologous recombination deficiency, through depletion of CtBP, in cells across multiple tumor types and sensitizes them to PARP inhibition. Thus, inhibition of BRD4 reverses resistance to PARP inhibitors and expands the potential use of PARP inhibitors.

Original languageEnglish (US)
Pages (from-to)401-416.e8
JournalCancer Cell
Volume33
Issue number3
DOIs
StatePublished - Mar 12 2018
Externally publishedYes

Fingerprint

Homologous Recombination
Mutation
Poly(ADP-ribose) Polymerase Inhibitors
Protein C
Neoplasms
DNA

Keywords

  • BRD4 inhibitor
  • CtBP-interacting protein
  • CtIP
  • homologous recombination
  • PARP inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. / Sun, Chaoyang; Yin, Jun; Fang, Yong; Chen, Jian; Jeong, Kang Jin; Chen, Xiaohua; Vellano, Christopher P.; Ju, Zhenlin; Zhao, Wei; Zhang, Dong; Lu, Yiling; Meric-Bernstam, Funda; Yap, Timothy A.; Hattersley, Maureen; O'Connor, Mark J.; Chen, Huawei; Fawell, Stephen; Lin, Shiaw Yih; Peng, Guang; Mills, Gordon.

In: Cancer Cell, Vol. 33, No. 3, 12.03.2018, p. 401-416.e8.

Research output: Contribution to journalArticle

Sun, C, Yin, J, Fang, Y, Chen, J, Jeong, KJ, Chen, X, Vellano, CP, Ju, Z, Zhao, W, Zhang, D, Lu, Y, Meric-Bernstam, F, Yap, TA, Hattersley, M, O'Connor, MJ, Chen, H, Fawell, S, Lin, SY, Peng, G & Mills, G 2018, 'BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency', Cancer Cell, vol. 33, no. 3, pp. 401-416.e8. https://doi.org/10.1016/j.ccell.2018.01.019
Sun, Chaoyang ; Yin, Jun ; Fang, Yong ; Chen, Jian ; Jeong, Kang Jin ; Chen, Xiaohua ; Vellano, Christopher P. ; Ju, Zhenlin ; Zhao, Wei ; Zhang, Dong ; Lu, Yiling ; Meric-Bernstam, Funda ; Yap, Timothy A. ; Hattersley, Maureen ; O'Connor, Mark J. ; Chen, Huawei ; Fawell, Stephen ; Lin, Shiaw Yih ; Peng, Guang ; Mills, Gordon. / BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. In: Cancer Cell. 2018 ; Vol. 33, No. 3. pp. 401-416.e8.
@article{6d4e5197f8fb4395a1b3ea5914b10757,
title = "BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency",
abstract = "Poly(ADP-ribose) polymerase inhibitors (PARPi) are selectively active in cells with homologous recombination (HR) deficiency (HRD) caused by mutations in BRCA1, BRCA2, and other pathway members. We sought small molecules that induce HRD in HR-competent cells to induce synthetic lethality with PARPi and extend the utility of PARPi. We demonstrated that inhibition of bromodomain containing 4 (BRD4) induced HRD and sensitized cells across multiple tumor lineages to PARPi regardless of BRCA1/2, TP53, RAS, or BRAF mutation status through depletion of the DNA double-stand break resection protein CtIP (C-terminal binding protein interacting protein). Importantly, BRD4 inhibitor (BRD4i) treatment reversed multiple mechanisms of resistance to PARPi. Furthermore, PARPi and BRD4i are synergistic in multiple in vivo models. Sun et al. show that inhibition of BRD4 induces homologous recombination deficiency, through depletion of CtBP, in cells across multiple tumor types and sensitizes them to PARP inhibition. Thus, inhibition of BRD4 reverses resistance to PARP inhibitors and expands the potential use of PARP inhibitors.",
keywords = "BRD4 inhibitor, CtBP-interacting protein, CtIP, homologous recombination, PARP inhibitor",
author = "Chaoyang Sun and Jun Yin and Yong Fang and Jian Chen and Jeong, {Kang Jin} and Xiaohua Chen and Vellano, {Christopher P.} and Zhenlin Ju and Wei Zhao and Dong Zhang and Yiling Lu and Funda Meric-Bernstam and Yap, {Timothy A.} and Maureen Hattersley and O'Connor, {Mark J.} and Huawei Chen and Stephen Fawell and Lin, {Shiaw Yih} and Guang Peng and Gordon Mills",
year = "2018",
month = "3",
day = "12",
doi = "10.1016/j.ccell.2018.01.019",
language = "English (US)",
volume = "33",
pages = "401--416.e8",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

AU - Sun, Chaoyang

AU - Yin, Jun

AU - Fang, Yong

AU - Chen, Jian

AU - Jeong, Kang Jin

AU - Chen, Xiaohua

AU - Vellano, Christopher P.

AU - Ju, Zhenlin

AU - Zhao, Wei

AU - Zhang, Dong

AU - Lu, Yiling

AU - Meric-Bernstam, Funda

AU - Yap, Timothy A.

AU - Hattersley, Maureen

AU - O'Connor, Mark J.

AU - Chen, Huawei

AU - Fawell, Stephen

AU - Lin, Shiaw Yih

AU - Peng, Guang

AU - Mills, Gordon

PY - 2018/3/12

Y1 - 2018/3/12

N2 - Poly(ADP-ribose) polymerase inhibitors (PARPi) are selectively active in cells with homologous recombination (HR) deficiency (HRD) caused by mutations in BRCA1, BRCA2, and other pathway members. We sought small molecules that induce HRD in HR-competent cells to induce synthetic lethality with PARPi and extend the utility of PARPi. We demonstrated that inhibition of bromodomain containing 4 (BRD4) induced HRD and sensitized cells across multiple tumor lineages to PARPi regardless of BRCA1/2, TP53, RAS, or BRAF mutation status through depletion of the DNA double-stand break resection protein CtIP (C-terminal binding protein interacting protein). Importantly, BRD4 inhibitor (BRD4i) treatment reversed multiple mechanisms of resistance to PARPi. Furthermore, PARPi and BRD4i are synergistic in multiple in vivo models. Sun et al. show that inhibition of BRD4 induces homologous recombination deficiency, through depletion of CtBP, in cells across multiple tumor types and sensitizes them to PARP inhibition. Thus, inhibition of BRD4 reverses resistance to PARP inhibitors and expands the potential use of PARP inhibitors.

AB - Poly(ADP-ribose) polymerase inhibitors (PARPi) are selectively active in cells with homologous recombination (HR) deficiency (HRD) caused by mutations in BRCA1, BRCA2, and other pathway members. We sought small molecules that induce HRD in HR-competent cells to induce synthetic lethality with PARPi and extend the utility of PARPi. We demonstrated that inhibition of bromodomain containing 4 (BRD4) induced HRD and sensitized cells across multiple tumor lineages to PARPi regardless of BRCA1/2, TP53, RAS, or BRAF mutation status through depletion of the DNA double-stand break resection protein CtIP (C-terminal binding protein interacting protein). Importantly, BRD4 inhibitor (BRD4i) treatment reversed multiple mechanisms of resistance to PARPi. Furthermore, PARPi and BRD4i are synergistic in multiple in vivo models. Sun et al. show that inhibition of BRD4 induces homologous recombination deficiency, through depletion of CtBP, in cells across multiple tumor types and sensitizes them to PARP inhibition. Thus, inhibition of BRD4 reverses resistance to PARP inhibitors and expands the potential use of PARP inhibitors.

KW - BRD4 inhibitor

KW - CtBP-interacting protein

KW - CtIP

KW - homologous recombination

KW - PARP inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85042881836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042881836&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2018.01.019

DO - 10.1016/j.ccell.2018.01.019

M3 - Article

C2 - 29533782

AN - SCOPUS:85042881836

VL - 33

SP - 401-416.e8

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 3

ER -